-
Johnson & Johnson Reports Q3 Sales Growth, Maintains Full-Year Guidance
•
US giant Johnson & Johnson (J&J, NYSE: JNJ) released its Q3 2022 financial report, showing global sales growth of 1.9% year-on-year (YOY) in reported terms to USD 23.8 billion. However, operational sales, excluding acquisitions, divestitures, and currency impacts, grew by 8.2%. This performance prompted the company to maintain its 2022…
-
Sichuan Biokin Pharma Plans IPO on STAR Board to Raise RMB 1.422 Billion
•
China-based Sichuan Biokin Pharmaceutical Co., Ltd is set to conduct an initial public offering (IPO) of 40.1 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise a total of RMB 1.422 billion (USD 196.6 million). The proceeds will be allocated towards the…
-
Mabwell Bioscience’s 9MW3011 Accepted for Review by China’s NMPA
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that its clinical filing for the Category 1 drug candidate 9MW3011 in β-Thalassemia and polycythemia vera has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step forward in the development of innovative treatments…
-
Zhiyi Biotechnology Receives FDA Clearance for SK10 in Chemotherapy-Induced Diarrhea
•
Guangzhou-based Zhiyi Biotechnology has announced receiving clearance from the US FDA for a clinical study of its SK10 (inactivated Bacteroides fragilis) in chemotherapy-induced diarrhea (CID). This marks a significant milestone in the development of live biotherapeutic products (LBPs) for addressing unmet medical needs. First-in-Class IND ApprovalNotably, this is the world’s…
-
Shanghai’s Hrain Biotechnology Plans IPO on STAR Board to Raise RMB 2.539 Billion
•
Shanghai-based Hrain Biotechnology Co., Ltd, a specialist in tumor immunotherapy, plans to conduct an initial public offering (IPO) of 50 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The offering is expected to raise RMB 2.539 billion (USD 352.6 million). The proceeds will be allocated towards cell…
-
Eucure Biopharma Partners with Syncromune on Intratumoral Immunotherapy
•
Eucure Biopharma, a wholly-owned subsidiary of Sino-US contract research organization (CRO) Biocytogen, has entered into an agreement with US firm Syncromune, an innovative pharma company focused on the development of next-generation tumor immunotherapies via intratumoral delivery. The collaboration aims to advance the development and commercialization of intratumoral immunotherapy based on…
-
Abogen Biosciences Receives UAE Clinical Trial Approval for Omicron BA.4/5 mRNA Vaccine
•
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, has announced receiving clinical trial approval in the United Arab Emirates (UAE) for its mRNA COVID-19 vaccine targeting the Omicron BA.4/5 variants. This approval marks a significant step in the global fight against the evolving COVID-19 pandemic.…
-
Shenzhen GeneBioHealth Secures USD 15M for Bio-Business Expansion
•
Shenzhen GeneBioHealth Co., Ltd, a China-based in-vitro diagnostic (IVD) medical device developer, has reportedly raised USD 15 million in a Series B+ financing round. The funds will be used to support bio-business development and product pipeline research and development (R&D). This investment underscores the company’s commitment to advancing its diagnostic…
-
CSPC’s Generic Xofluza Gains NMPA Approval Amid Roche Patent Dispute
•
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) has obtained market approval from the National Medical Products Administration (NMPA) for its generic version of Roche’s (SWX: ROG) Xofluza (baloxavir marboxil) on October 11, 2022. This approval marks a significant development in the availability of generic influenza treatments in China. However,…
-
Gracell Biotechnologies Initiates Phase II Dosing for GC007g in B-ALL Patients
•
China-based Gracell Biotechnologies Inc. has announced the first patient dosing in the Phase II portion of its registrational Phase I/II clinical study assessing GC007g for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in China. This milestone marks a significant step forward in the development of innovative treatments…
-
Henlius Biotech Gains NMPA Approval for Phase I Trial of HLX60 in Solid Tumors and Lymphomas
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving approval from the National Medical Products Administration (NMPA) to conduct a Phase I clinical study for its HLX60 in solid tumors and lymphomas in mainland China. This marks a significant step forward in the development of innovative treatments for these challenging…
-
PureID Medical Technology Secures RMB 100M Series B Funding
•
PureID Medical Technology Co., Ltd, a medical device compliance service provider based in Guangzhou, has reportedly raised over RMB 100 million (USD 13.89 million) in a Series B financing round. The round was led by Legend Capital, with a contribution from existing investor Bayland Capital. The proceeds will be used…
-
Sinocelltech’s COVID-19 Vaccines SCTV01C and SCTV01E Show Promising Phase III Results
•
China-based Sinocelltech Group Ltd (SHA: 688520) has announced the preliminary interim analysis results of a Phase III clinical study for its in-house developed recombinant COVID-19 vaccines. The study evaluated the bivalent (Alpha + Beta variants) S trimer protein vaccine SCTV01C and the quadrivalent (Alpha + Beta + Delta + Omicron…
-
Jemincare’s Sonidegib Receives First Prescriptions in China for Basal Cell Carcinoma
•
China-based Jiangxi Jemincare Group has announced the first prescriptions in China for its sonidegib, a smoothened (Smo) inhibitor used to treat basal cell carcinoma (BCC). The initial batch of prescriptions covers more than 50 special drug pharmacies and online platforms across the country. This marks a significant milestone in the…
-
Salus Biomed Raises Over RMB 100M in Pre-Series A Financing
•
Salus Biomed, a sequencing and spatial omics platform provider based in Guangdong, has reportedly raised over RMB 100 million (USD 13.89 million) in a Pre-Series A financing round. The funding will support regulatory filings and ongoing research and development of its gene sequencing platform and super-resolution spatial omics products, as…
-
Haisco Pharma’s Ciprofol Injection Gains NMPA Approval for Gynecology Use
•
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from the National Medical Products Administration (NMPA) for its Category 1 product, ciprofol injection, for use in gynecology outpatient sedation/anesthesia. This approval expands the indications for ciprofol, further solidifying its position in the anesthetic market. Drug…
-
ScienCare Pharma’s Naltrexone Implant Prioritized for Review by CDE
•
The Center for Drug Evaluation (CDE) website indicates that the market filing by China-based Shenzhen ScienCare Pharmaceutical Co., Ltd for its naltrexone implant has been prioritized for review. The drug, used to prevent relapse among opioid-dependent patients after detoxification, was awarded priority status as a “breakthrough therapy.” This marks a…
-
Grand Pharma’s TLX591-CDx Approved for Prostate Cancer Diagnosis in China
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its Investigational New Drug (IND) filing for TLX591-CDx (Illuccix, gallium Ga 68 PSMA-11), a radionuclide-drug conjugate (RDC) for the diagnosis of prostate cancer, has been approved by the National Medical Products Administration (NMPA). This approval marks a significant step forward…
-
Kunshi Biotechnology Raises Angel Funding for Engineered Macrophage Platform
•
China-based Kunshi Biotechnology (Shenzhen) Co., Ltd, a company specializing in gene editing, biomaterials, and synthetic biology-driven platforms for engineered macrophages to treat solid tumors, has reportedly raised “tens of millions” of renminbi in an angel financing round. The funding was led by ASB Ventures, Riemann Hypothesis, and other investors. The…
-
Akeso Biopharma’s Cadonilimab Recommended as First-Line Treatment for Cervical Cancer
•
China-based biotech Akeso Biopharma (HKG: 9926) has revealed that its cadonilimab (AK104) has been included as the first recommended treatment for second-line recurrent or metastatic cervical cancer in the Chinese Society of Clinical Oncology’s (CSCO) cervical cancer diagnosis and treatment guidelines (2022). This marks a significant milestone in the recognition…
